Natália Noronha Ferreira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Natália Noronha Ferreira has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Maria Palmira Daflon Gremião
School of Pharmaceutical Sciences, São Paulo State University, Rodovia Araraquara—Jaú Km 1, Araraquara 14800-903, SP, Brazil
8 shared publications - Fernanda Isadora Boni
Universidade Federal do Rio Grande do Sul (UFRGS), Brasil
6 shared publications - Leonardo Miziara Barboza Ferreira
School of Pharmaceutical Sciences, São Paulo State University, Rodovia Araraquara—Jaú Km 1, Araraquara 14800-903, SP, Brazil
5 shared publications - Beatriz Stringhetti Ferreira Cury
School of Pharmaceutical Sciences, São Paulo State University (UNESP)
4 shared publications - Fátima Baltazar
Life and Health Sciences Research Institute (ICVS) School of Medicine University of Minho Braga Portugal
4 shared publications - Rui Luis Reis
University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine
4 shared publications
Latest Publications
- Open Access
- 13 May 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
Photoresponsive Nanocarriers for Potentiating Tuberculosis Therapy
Drug-resistant and multidrug-resistant tuberculosis (TB) remain major challenges to effective treatment. Given that TB arises from complex bacterial survival mechanisms, addressing this multifactorial disease requires innovative and combinatorial therapeutic approaches. Although various strategies have been employed to overcome these issues, concerns regarding therapeutic efficacy persist due to the prolonged treatment duration and high toxicity. Here, we developed photoresponsive nanocarriers coencapsulating isoniazid (INH) and rifampicin (RIF), with or without gold nanorods (AuNRs), as a multifunctional platform for laser-assisted TB therapy. AuNRs were synthesized and functionalized with PLGA-SH to enable photothermal activation and integration into polymeric carriers. The resulting systems exhibited an average size of approximately 180 nm, zeta potentials around −28 mV, particle concentrations on the order of 1011 particles mL–1, as measured by nanoparticle tracking analysis, and average encapsulation efficiencies of 90% for both drugs. In vitro, photoactivated nanocarriers significantly reduced Mycobacterium tuberculosis burden in murine alveolar epithelial (MLE-15) cells and macrophages (BMDMs), as well as in human macrophages (THP-1), without inducing cytotoxicity. TB preclinical models demonstrated that laser-triggered nanocarriers significantly reduced pulmonary bacterial load in infected mice compared with untreated groups, even at low doses. These findings demonstrate that the formulation’s therapeutic efficacy depends on photothermal activation and support its potential as an adjuvant strategy for precision, light-assisted TB treatment, thereby reducing systemic exposure and minimizing toxicity.
- 13 May 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
Open AccessPhotoresponsive Nanocarriers for Potentiating Tuberculosis Therapy
Drug-resistant and multidrug-resistant tuberculosis (TB) remain major challenges to effective treatment. Given that TB arises from complex bacterial survival mechanisms, addressing this multifactorial disease requires innovative and combinatorial therapeutic approaches. Although various strategies have been employed to overcome these issues, concerns regarding therapeutic efficacy persist due to the prolonged treatment duration and high toxicity. Here, we developed photoresponsive nanocarriers coencapsulating isoniazid (INH) and rifampicin (RIF), with or without gold nanorods (AuNRs), as a multifunctional platform for laser-assisted TB therapy. AuNRs were synthesized and functionalized with PLGA-SH to enable photothermal activation and integration into polymeric carriers. The resulting systems exhibited an average size of approximately 180 nm, zeta potentials around −28 mV, particle concentrations on the order of 1011 particles mL–1, as measured by nanoparticle tracking analysis, and average encapsulation efficiencies of 90% for both drugs. In vitro, photoactivated nanocarriers significantly reduced Mycobacterium tuberculosis burden in murine alveolar epithelial (MLE-15) cells and macrophages (BMDMs), as well as in human macrophages (THP-1), without inducing cytotoxicity. TB preclinical models demonstrated that laser-triggered nanocarriers significantly reduced pulmonary bacterial load in infected mice compared with untreated groups, even at low doses. These findings demonstrate that the formulation’s therapeutic efficacy depends on photothermal activation and support its potential as an adjuvant strategy for precision, light-assisted TB treatment, thereby reducing systemic exposure and minimizing toxicity.
- Open Access
Computational Modeling to Guide the Design of Mesalazine Nanoparticles Tailored for the Incorporation of Chitosan
The main objective of treatment with MSZ is to ensure that the drug reaches the colon, where it exerts its therapeutic effect. However, due to pH variation throughout the gastrointestinal tract and the risk of degradation or premature absorption, a considerable portion of the drug may not reach the colon in adequate concentrations. In this study, computational modeling was combined with experimental approaches for the design of MSZ nanoparticles (MSZ-NPs) suitable for chitosan (CS) incorporation. Quantum chemical calculations and molecular modeling revealed the importance of pH as a nucleation determinant and in the growth of the MSZ complexes. At pH~1.0, cationic clusters predominated, characterized by higher interaction energies and larger volumes/surface areas. At pH~4.0, zwitterionic clusters were stabilized, whereas at pH~6.0, anionic clusters formed the most compact assemblies, with the smallest calculated volume (4817 Å3) and surface area (2458 Å2). Consistent with the computational predictions, experimental approaches showed a progressive reduction in particle size with increasing pH. Nanoparticles prepared at pH 1.5 (F1.5), 4.0 (F4.0), and 6.0 (F6.0) showed mean diameters of 937, 556, and 146 nm, respectively, with corresponding zeta potentials (ZPs) of +8.5, −22.3, and −31.6 mV. Drug precipitation efficiency was as follows: 51.6% to F1.5, 95.1% to F4.0, and 75.5% to F6.0. F4.0 and F6.0 were selected to evaluate the effect of CS incorporation. The CS incorporation resulted in a reversal in the zeta potential in formulations prepared at pH 4.0 and 6.0. When 5% CS was added during nanoparticle formation (F4.0-5 and F6.0-5), the particles were smaller in diameter and had a lower positive ZP. F6.0-5 achieved the most favorable properties and strong mucoadhesion, evidenced by the ZP shift from +26.8 mV to −1.9 mV at a pH of 6.8. The modeling and experimental approaches guided the rational design of MSZ-NPs for CS incorporation, yielding mucoadhesive nanoparticles for colon-targeted drug delivery.
Open AccessComputational Modeling to Guide the Design of Mesalazine Nanoparticles Tailored for the Incorporation of Chitosan
The main objective of treatment with MSZ is to ensure that the drug reaches the colon, where it exerts its therapeutic effect. However, due to pH variation throughout the gastrointestinal tract and the risk of degradation or premature absorption, a considerable portion of the drug may not reach the colon in adequate concentrations. In this study, computational modeling was combined with experimental approaches for the design of MSZ nanoparticles (MSZ-NPs) suitable for chitosan (CS) incorporation. Quantum chemical calculations and molecular modeling revealed the importance of pH as a nucleation determinant and in the growth of the MSZ complexes. At pH~1.0, cationic clusters predominated, characterized by higher interaction energies and larger volumes/surface areas. At pH~4.0, zwitterionic clusters were stabilized, whereas at pH~6.0, anionic clusters formed the most compact assemblies, with the smallest calculated volume (4817 Å3) and surface area (2458 Å2). Consistent with the computational predictions, experimental approaches showed a progressive reduction in particle size with increasing pH. Nanoparticles prepared at pH 1.5 (F1.5), 4.0 (F4.0), and 6.0 (F6.0) showed mean diameters of 937, 556, and 146 nm, respectively, with corresponding zeta potentials (ZPs) of +8.5, −22.3, and −31.6 mV. Drug precipitation efficiency was as follows: 51.6% to F1.5, 95.1% to F4.0, and 75.5% to F6.0. F4.0 and F6.0 were selected to evaluate the effect of CS incorporation. The CS incorporation resulted in a reversal in the zeta potential in formulations prepared at pH 4.0 and 6.0. When 5% CS was added during nanoparticle formation (F4.0-5 and F6.0-5), the particles were smaller in diameter and had a lower positive ZP. F6.0-5 achieved the most favorable properties and strong mucoadhesion, evidenced by the ZP shift from +26.8 mV to −1.9 mV at a pH of 6.8. The modeling and experimental approaches guided the rational design of MSZ-NPs for CS incorporation, yielding mucoadhesive nanoparticles for colon-targeted drug delivery.
- 25 March 2025
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 16 (9) , 1-16
Optimized mucus adhesion and penetration of lipid-polymer nanoparticles enables effective nose-to-brain delivery of perillyl alcohol for glioblastoma therapy
The delivery of drugs directly from the nose to the brain has been explored for the treatment of neurological diseases, such as glioblastoma, by overcoming the blood–brain barrier. Nanocarriers have demonstrated outstanding ability to enhance drug bioavailability in the brain, following intranasal administration. However, the performance of these nanosystems may be hindered by inadequate interactions with the nasal mucosa, limiting their effectiveness in reaching the olfactory region, and consequently, the translocation of particles to the brain. Here, we designed hybrid lipid-polymer nanoparticles (LPNP), containing the cationic lipid DOTAP and the triblock copolymer Pluronic® F127 to combine the mucoadhesiveness and mucus-penetrating properties. Perillyl alcohol (POH), a molecule currently under clinical trials against glioblastoma, via intranasal route, was entrapped in the nanoparticles. LPNP-POH exhibited a balanced profile of mucus adhesion and penetration, suggesting that the formulation may enhance mucosal retention while maintaining effective mucus diffusivity. In vivo evaluations displayed higher translocation of LPNP-POH from the nasal cavity to the brain. LPNP-POH resulted in a 2.5-fold increase in the concentration of perillyl acid (a primary metabolite of POH) in the cerebral tissue compared to the free drug. In vitro assays demonstrated that LPNP-POH increased the cytotoxicity and reduced the tumor growth of U87MG glioma cells. These results highlighted that the engineered formulation, with optimized mucoadhesiveness and mucus penetration properties, improved nose-to-brain delivery of POH, offering a promising potential for glioblastoma therapy. Graphical abstract
- 25 March 2025
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 16 (9) , 1-16
Optimized mucus adhesion and penetration of lipid-polymer nanoparticles enables effective nose-to-brain delivery of perillyl alcohol for glioblastoma therapy
The delivery of drugs directly from the nose to the brain has been explored for the treatment of neurological diseases, such as glioblastoma, by overcoming the blood–brain barrier. Nanocarriers have demonstrated outstanding ability to enhance drug bioavailability in the brain, following intranasal administration. However, the performance of these nanosystems may be hindered by inadequate interactions with the nasal mucosa, limiting their effectiveness in reaching the olfactory region, and consequently, the translocation of particles to the brain. Here, we designed hybrid lipid-polymer nanoparticles (LPNP), containing the cationic lipid DOTAP and the triblock copolymer Pluronic® F127 to combine the mucoadhesiveness and mucus-penetrating properties. Perillyl alcohol (POH), a molecule currently under clinical trials against glioblastoma, via intranasal route, was entrapped in the nanoparticles. LPNP-POH exhibited a balanced profile of mucus adhesion and penetration, suggesting that the formulation may enhance mucosal retention while maintaining effective mucus diffusivity. In vivo evaluations displayed higher translocation of LPNP-POH from the nasal cavity to the brain. LPNP-POH resulted in a 2.5-fold increase in the concentration of perillyl acid (a primary metabolite of POH) in the cerebral tissue compared to the free drug. In vitro assays demonstrated that LPNP-POH increased the cytotoxicity and reduced the tumor growth of U87MG glioma cells. These results highlighted that the engineered formulation, with optimized mucoadhesiveness and mucus penetration properties, improved nose-to-brain delivery of POH, offering a promising potential for glioblastoma therapy. Graphical abstract
- Open Access
- 18 December 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (1) , 484-499
Nose-to-Brain Delivery of Biomimetic Nanoparticles for Glioblastoma Targeted Therapy
Glioblastoma (GBM) is an extremely aggressive form of brain cancer that remains challenging to treat, especially owing to the lack of effective targeting and drug delivery concerns. Due to its anatomical advantages, the nose-to-brain strategy is an interesting route for drug delivery. Nanoengineering has provided technological tools and innovative strategies to overcome biotechnological limitations, which is promising for improving the effectiveness of conventional therapies. Herein, we designed a biomimetic multifunctional nanostructure produced by polymeric poly(d,l-lactic-co-glycolic) acid (PLGA) core loaded with Temozolomide (TMZ) coated with cell membrane isolated from glioma cancer cells. The developed nanostructures (NP-MB) were fully characterized, and their biological performance was investigated extensively. The results indicate that NP-MB could control TMZ release and promote TMZ permeation in the ex vivo nasal porcine mucosa. The higher cytotoxicity of NP-MB in different glioma cell lines, particularly against U251 cells, reinforces their potential for homotypic targeting. The chicken chorioallantoic membrane assay revealed a tumor size reduction and antiangiogenic activity. In vivo biodistribution studies showed that NP-MB effectively reaches the brain following nasal administration. These findings suggest that NP-MB holds promise as a biomimetic nanoplatform for effective targeting and homotypic recognition in GBM therapy with high potential for clinical translation.
- 18 December 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (1) , 484-499
Open AccessNose-to-Brain Delivery of Biomimetic Nanoparticles for Glioblastoma Targeted Therapy
Glioblastoma (GBM) is an extremely aggressive form of brain cancer that remains challenging to treat, especially owing to the lack of effective targeting and drug delivery concerns. Due to its anatomical advantages, the nose-to-brain strategy is an interesting route for drug delivery. Nanoengineering has provided technological tools and innovative strategies to overcome biotechnological limitations, which is promising for improving the effectiveness of conventional therapies. Herein, we designed a biomimetic multifunctional nanostructure produced by polymeric poly(d,l-lactic-co-glycolic) acid (PLGA) core loaded with Temozolomide (TMZ) coated with cell membrane isolated from glioma cancer cells. The developed nanostructures (NP-MB) were fully characterized, and their biological performance was investigated extensively. The results indicate that NP-MB could control TMZ release and promote TMZ permeation in the ex vivo nasal porcine mucosa. The higher cytotoxicity of NP-MB in different glioma cell lines, particularly against U251 cells, reinforces their potential for homotypic targeting. The chicken chorioallantoic membrane assay revealed a tumor size reduction and antiangiogenic activity. In vivo biodistribution studies showed that NP-MB effectively reaches the brain following nasal administration. These findings suggest that NP-MB holds promise as a biomimetic nanoplatform for effective targeting and homotypic recognition in GBM therapy with high potential for clinical translation.
- Open Access
- 2 February 2023
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 11, 1120179
Using design of experiments (DoE) to optimize performance and stability of biomimetic cell membrane-coated nanostructures for cancer therapy
Introduction: Cell membrane-covered biomimetic nanosystems have allowed the development of homologous nanostructures to bestow nanoparticles with enhanced biointerfacing capabilities. The stability of these structures, however, still represents a challenge for the scientific community. This study is aimed at developing and optimizing cell derived membrane-coated nanostructures upon applying design of experiments (DoE) to improve the therapeutic index by homotypic targeting in cancer cells.Methods: Important physicochemical features of the extracted cell membrane from tumoral cells were assessed by mass spectrometry-based proteomics. PLGA-based nanoparticles encapsulating temozolomide (TMZ NPs) were successfully developed. The coating technology applying the isolated U251 cell membrane (MB) was optimized using a fractional two-level three-factor factorial design. All the formulation runs were systematically characterized regarding their diameter, polydispersity index (PDI), and zeta potential (ZP). Experimental conditions generated by DoE were also subjected to morphological studies using negative-staining transmission electron microscopy (TEM). Its short-time stability was also assessed. MicroRaman and Fourier-Transform Infrared (FTIR) spectroscopies and Confocal microscopy were used as characterization techniques for evaluating the NP-MB nanostructures. Internalization studies were carried out to evaluate the homotypic targeting ability.Results and Discussion: The results have shown that nearly 80% of plasma membrane proteins were retained in the cell membrane vesicles after the isolation process, including key proteins to the homotypic binding. DoE analysis considering acquired TEM images reveals that condition run five should be the best-optimized procedure to produce the biomimetic cell-derived membrane-coated nanostructure (NP-MB). Storage stability for at least two weeks of the biomimetic system is expected once the original characteristics of diameter, PDI, and ZP, were maintained. Raman, FTIR, and confocal characterization results have shown the successful encapsulation of TMZ drug and provided evidence of the effective coating applying the MB. Cell internalization studies corroborate the proteomic data indicating that the optimized NP-MB achieved specific targeting of homotypic tumor cells. The structure should retain the complex biological functions of U251 natural cell membranes while exhibiting physicochemical properties suitable for effective homotypic recognition.Conclusion: Together, these findings provide coverage and a deeper understanding regarding the dynamics around extracted cell membrane and polymeric nanostructures interactions and an in-depth insight into the cell membrane coating technology and the development of optimized biomimetic and bioinspired nanostructured systems.
- 2 February 2023
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 11, 1120179
Open AccessUsing design of experiments (DoE) to optimize performance and stability of biomimetic cell membrane-coated nanostructures for cancer therapy
Introduction: Cell membrane-covered biomimetic nanosystems have allowed the development of homologous nanostructures to bestow nanoparticles with enhanced biointerfacing capabilities. The stability of these structures, however, still represents a challenge for the scientific community. This study is aimed at developing and optimizing cell derived membrane-coated nanostructures upon applying design of experiments (DoE) to improve the therapeutic index by homotypic targeting in cancer cells.Methods: Important physicochemical features of the extracted cell membrane from tumoral cells were assessed by mass spectrometry-based proteomics. PLGA-based nanoparticles encapsulating temozolomide (TMZ NPs) were successfully developed. The coating technology applying the isolated U251 cell membrane (MB) was optimized using a fractional two-level three-factor factorial design. All the formulation runs were systematically characterized regarding their diameter, polydispersity index (PDI), and zeta potential (ZP). Experimental conditions generated by DoE were also subjected to morphological studies using negative-staining transmission electron microscopy (TEM). Its short-time stability was also assessed. MicroRaman and Fourier-Transform Infrared (FTIR) spectroscopies and Confocal microscopy were used as characterization techniques for evaluating the NP-MB nanostructures. Internalization studies were carried out to evaluate the homotypic targeting ability.Results and Discussion: The results have shown that nearly 80% of plasma membrane proteins were retained in the cell membrane vesicles after the isolation process, including key proteins to the homotypic binding. DoE analysis considering acquired TEM images reveals that condition run five should be the best-optimized procedure to produce the biomimetic cell-derived membrane-coated nanostructure (NP-MB). Storage stability for at least two weeks of the biomimetic system is expected once the original characteristics of diameter, PDI, and ZP, were maintained. Raman, FTIR, and confocal characterization results have shown the successful encapsulation of TMZ drug and provided evidence of the effective coating applying the MB. Cell internalization studies corroborate the proteomic data indicating that the optimized NP-MB achieved specific targeting of homotypic tumor cells. The structure should retain the complex biological functions of U251 natural cell membranes while exhibiting physicochemical properties suitable for effective homotypic recognition.Conclusion: Together, these findings provide coverage and a deeper understanding regarding the dynamics around extracted cell membrane and polymeric nanostructures interactions and an in-depth insight into the cell membrane coating technology and the development of optimized biomimetic and bioinspired nanostructured systems.
- 1 December 2021
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 66
Rational design of nanocarriers based on gellan gum/retrograded starch exploiting polyelectrolyte complexation and ionic cross-linking processes: A potential technological platform for oral delivery of bevacizumab
- 1 December 2021
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 66
Rational design of nanocarriers based on gellan gum/retrograded starch exploiting polyelectrolyte complexation and ionic cross-linking processes: A potential technological platform for oral delivery of bevacizumab
- 1 June 2021
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 603, 120714
Nose-to-brain co-delivery of drugs for glioblastoma treatment using nanostructured system
- 1 June 2021
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 603, 120714
Nose-to-brain co-delivery of drugs for glioblastoma treatment using nanostructured system
- Open Access
- 19 March 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (3) , 407
Ionic Cross-Linking as a Strategy to Modulate the Properties of Oral Mucoadhesive Microparticles Based on Polysaccharide Blends
Polymer blends of gellan gum (GG)/retrograded starch(RS) and GG/pectin (P) were cross-linked with calcium, aluminum, or both to prepare mucoadhesive microparticles as oral carriers of drugs or nano systems. Cross-linking with different cations promoted different effects on each blend, which can potentially be explored as novel strategies for modulating physical–chemical and mucoadhesive properties of microparticles. Particles exhibited spherical shapes, diameters from 888 to 1764 µm, and span index values lower than 0.5. Blends of GG:P cross-linked with aluminum resulted in smaller particles than those obtained by calcium cross-linking. GG:RS particles exhibited larger sizes, but cross-linking this blend with calcium promoted diameter reduction. The uptake rates of acid medium were lower than phosphate buffer (pH 6.8), especially GG:RS based particles cross-linked with calcium. On the other hand, particles based on GG:P cross-linked with calcium absorbed the highest volume of acid medium. The percentage of systems erosion was higher in acid medium, but apparently occurred in the outermost layer of the particle. In pH 6.8, erosion was lower, but caused expressive swelling of the matrixes. Calcium cross-linking of GG:RS promoted a significantly reduction on enzymatic degradation at both pH 1.2 and 6.8, which is a promising feature that can provide drug protection against premature degradation in the stomach. In contrast, GG:P microparticles cross-linked with calcium suffered high degradation at both pH values, an advantageous feature for quickly releasing drugs at different sites of the gastrointestinal tract. The high mucoadhesive ability of the microparticles was evidenced at both pH values, and the Freundlich parameters indicated stronger particle–mucin interactions at pH 6.8.
- 19 March 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (3) , 407
Open AccessIonic Cross-Linking as a Strategy to Modulate the Properties of Oral Mucoadhesive Microparticles Based on Polysaccharide Blends
Polymer blends of gellan gum (GG)/retrograded starch(RS) and GG/pectin (P) were cross-linked with calcium, aluminum, or both to prepare mucoadhesive microparticles as oral carriers of drugs or nano systems. Cross-linking with different cations promoted different effects on each blend, which can potentially be explored as novel strategies for modulating physical–chemical and mucoadhesive properties of microparticles. Particles exhibited spherical shapes, diameters from 888 to 1764 µm, and span index values lower than 0.5. Blends of GG:P cross-linked with aluminum resulted in smaller particles than those obtained by calcium cross-linking. GG:RS particles exhibited larger sizes, but cross-linking this blend with calcium promoted diameter reduction. The uptake rates of acid medium were lower than phosphate buffer (pH 6.8), especially GG:RS based particles cross-linked with calcium. On the other hand, particles based on GG:P cross-linked with calcium absorbed the highest volume of acid medium. The percentage of systems erosion was higher in acid medium, but apparently occurred in the outermost layer of the particle. In pH 6.8, erosion was lower, but caused expressive swelling of the matrixes. Calcium cross-linking of GG:RS promoted a significantly reduction on enzymatic degradation at both pH 1.2 and 6.8, which is a promising feature that can provide drug protection against premature degradation in the stomach. In contrast, GG:P microparticles cross-linked with calcium suffered high degradation at both pH values, an advantageous feature for quickly releasing drugs at different sites of the gastrointestinal tract. The high mucoadhesive ability of the microparticles was evidenced at both pH values, and the Freundlich parameters indicated stronger particle–mucin interactions at pH 6.8.
- 1 February 2021
- Published by Elsevier in Carbohydrate Polymers
- Vol. 254, 117444
Computational and experimental approaches for chitosan-based nano PECs design: Insights on a deeper comprehension of nanostructure formation
- 1 February 2021
- Published by Elsevier in Carbohydrate Polymers
- Vol. 254, 117444
Computational and experimental approaches for chitosan-based nano PECs design: Insights on a deeper comprehension of nanostructure formation